I'll give you three reasons, and then I'll tell you where the argument gets uncomfortable for us here.
The ESOPEC trail put the two strategies head to head in oesophageal adenocarcinoma and FLOT was better on overall survival, which was roughly 66 months against 37. The Neo-AEGIS had already failed to show trimodality doing better than perioperative chemotherapy, and the TOPGEAR trial found no gain from bolting chemoradiation onto a perioperative chemotherapy backbone. Putting those three pieces of evidence together, in adenocarcinoma, it is the systemic component that works. Remember also that CROSS drew much of its pathological complete response signal from its squamous patients, not its adenocarcinomas.
The second is where this tumour will fail. A cT3N1 junctional adenocarcinoma recurs in the peritoneum and the liver. Local control is not my main problem. FLOT4 gave 50 months against 35 for ECF/ECX, and it included Siewert I through III.
The third is surgical. If I irradiate a Siewert II lesion I am putting dose through the proximal stomach — the very tissue my surgeon intends to pull up as a conduit — along with heart and lung. In a unit that does not do high-volume oesophagectomy, I would rather not hand the surgeon a devascularised conduit.
Now the uncomfortable part. FLOT asks this man for eight day-case visits over sixteen weeks, an ambulatory pump, central access, and almost certainly G-CSF, because grade 3/4 neutropenia runs around half. CROSS asks for weekly carboplatin and paclitaxel — genuinely cheap drugs — but also twenty-three daily fractions, which for a trader from Ile-Ife means five weeks of lodging and five weeks of lost income. And if the linac goes down, a 23-fraction plan quietly becomes a six-week plan with a treatment gap. When you cost these two options honestly for a man paying from his own pocket, the drug price is often the smaller number.
So: FLOT, with oxaliplatin modified — but only after I have fed him. With 14 kg lost and near-total dysphagia he is sarcopenic and functionally ECOG 2, and I will not give a triplet to that man. If two weeks of jejunal feeding does not bring him to ECOG 0–1, I switch to the carboplatin/paclitaxel backbone, which gives me a tolerable doublet and lets me decide about radiotherapy as a separate question.
What I will not accept is the surgical team's plan to operate now. Upfront resection is the losing arm of every modern trial in this disease. Obstruction is an indication for feeding access, not for an emergency oesophagogastrectomy in a starved patient.